Neovasc Inc. P/B ratio

P/B ratio of NVCN for past 10 years: annual, quarterly and twelve month trailing (TTM) including P/B ratio growth rates and interactive chart. Measures the relationship between price and book value per share. Book value is the equity or owner's capital that is invested in a business. If a stock has a price of $10 and a book value per share of $10, the ratio is 1. Stock selling below a P/B of 1 can be a bargain, as the market price has declined below the net asset value of the business. It is more applicable to financial companies like banks and insurers, as their assets and liabilities are valued at market and the book value thus more accuraterly represents reality.


Highlights and Quick Summary

Current P/B ratio of Neovasc Inc. is 0.61 (as of December 31, 2021)
  • P/B ratio for the quarter ending March 31, 2022 was 0.67 (a 8.77% increase compared to previous quarter)
  • Year-over-year quarterly P/B ratio decreased by -32.1%
  • Annual P/B ratio for 2021 was 0.61 (a -94.8% decrease from previous year)
  • Annual P/B ratio for 2020 was 11.77 (a Infinity% increase from previous year)
  • Annual P/B ratio for 2019 was 0.0 (a NaN% decrease from previous year)
Visit stockrow.com/NVCN for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical P/B ratio of Neovasc Inc.

Most recent P/B ratioof NVCN including historical data for past 10 years.

Interactive Chart of P/B ratio of Neovasc Inc.

Neovasc Inc. P/B ratio for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2022 0.67
2021 0.61 0.86 0.98 0.74 0.61
2020 11.77 65.38 0.0 0.0 11.77
2019 0.0 0.0 0.0 0.0 0.0
2018 0.0 0.0 0.0 0.0 0.0
2017 0.0 0.0 0.0 0.0 0.0
2016 0.0 0.0 0.0 5.53 0.0
2015 5.24 4.88 5.82 6.67 5.24
2014 20.39 13.74 13.49 10.58 20.39
2013 32.8 16.45 16.03 17.28 32.8
2012 10.84 19.5 11.28 13.21 10.84
2011 10.03 10.03

Business Profile of Neovasc Inc.

Sector: Healthcare
Industry: Medical Devices
Neovasc Inc., a specialty medical device company, develops, manufactures, and markets products for cardiovascular marketplace in Europe and internationally. Its products include the Tiara technology for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina. The company was formerly known as Medical Ventures Corp. and changed its name to Neovasc Inc. in July 2008. Neovasc Inc. was incorporated in 2000 and is headquartered in Richmond, Canada.